

anti- CEBPA antibody

Product Information

Catalog No.: FNab01579

Size: 100μg Form: liquid

Purification: Immunogen affinity purified

Purity: ≥95% as determined by SDS-PAGE

Host: Rabbit

Clonality: polyclonal

Clone ID: None IsoType: IgG

Storage: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12

months (Avoid repeated freeze / thaw cycles.)

Background

Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes(PubMed:11242107). During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors(CMP) to granulocyte/monocyte progenitors(GMP). Critical for the proper development of the liver and the lung(By similarity). Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage(By similarity). To regulate these different processes at the proper moment and tissue, interplays with other transcription factors and modulators. Downregulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is critical for its ability to induce adipocyte and granulocyte terminal differentiation. Reciprocally E2F1 blocks adipocyte differentiation by binding to specific promoters and repressing CEBPA binding to its target gene promoters. Proliferation arrest also depends on a functional binding to SWI/SNF complex(PubMed:14660596). In liver, regulates gluconeogenesis and lipogenesis through different mechanisms. To regulate gluconeogenesis, functionally cooperates with FOXO1 binding to IRE-controlled promoters and regulating the expression of target genes such as PCK1 or G6PC. To modulate lipogenesis, interacts and transcriptionally synergizes with SREBF1 in promoter activation of specific lipogenic target genes such as ACAS2. In adipose tissue, seems to act as FOXO1 coactivator accessing to ADIPOQ promoter through FOXO1 binding sites(By

Wuhan Fine Biotech Co., Ltd.

B9 Bld, High-Tech Medical Devices Park, No. 818 GaoxinAve.East Lake High-Tech Development Zone.Wuhan, Hubei, China(430206)

Tel:(0086)027-87384275 Fax: (0086)027-87800889 www.fn-test.com



similarity). Isoform 3: Can act as dominant-negative. Binds DNA and have transctivation activity, even if much less efficiently than isoform 2. Does not inhibit cell proliferation(PubMed:14660596). Isoform 4: Directly and specifically enhances ribosomal DNA transcription interacting with RNA polymerase I-specific cofactors and inducing histone acetylation.

Immunogen information

Immunogen: CCAAT/enhancer binding protein(C/EBP), alpha

Synonyms: CEBP

Observed MW: 43-45 kDa

UniprotID: P49715


Application

Reactivity: Human, Mouse, Rat

Tested Application: ELISA, WB

Recommended dilution: WB: 1:500-1:2000

Image:



L02 cells were subjected to SDS PAGE followed by western blot with FNab01579(CEBPA antibody) at dilution of 1:500

Wuhan Fine Biotech Co., Ltd.

B9 Bld, High-Tech Medical Devices Park, No. 818 GaoxinAve.East Lake High-Tech Development Zone.Wuhan, Hubei, China(430206)

Tel:(0086)027-87384275 Fax: (0086)027-87800889 www.fn-test.com



Wuhan Fine Biotech Co., Ltd.

B9 Bld, High-Tech Medical Devices Park, No. 818 GaoxinAve.East Lake High-Tech Development Zone.Wuhan, Hubei, China(430206)

Tel: (0086)027-87384275 Fax: (0086)027-87800889 <u>www.fn-test.com</u>